Evidence map›Paper›PMID 26827257›Full record

ArticleJournal of substance abuse treatment2016

Low Pretreatment Impulsivity and High Medication Adherence Increase the Odds of Abstinence in a Trial of N-Acetylcysteine in Adolescents with Cannabis Use Disorder.

Jessica P Bentzley, Rachel L Tomko, Kevin M Gray

Open access · bronzeAbstract read
In one paragraph

Article in Journal of substance abuse treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pharmacotherapies for cannabis dependence.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Which came first: Cannabis use or deficits in impulse control?Progress in neuro-psychopharmacology & biological psychiatry · 2021
    Review
  10. Review
  11. Pharmacological Treatment of Youth Substance Use Disorders.Journal of child and adolescent psychopharmacology · 2019
    Review
  12. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jessica P BentzleyDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 125 Doughty Street, Suite 190, MSC861, Charleston, SC 29425, USA.
Rachel L TomkoDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 125 Doughty Street, Suite 190, MSC861, Charleston, SC 29425, USA.
Kevin M GrayDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 125 Doughty Street, Suite 190, MSC861, Charleston, SC 29425, USA. Electronic address: graykm@musc.edu.
Medical University of South Carolina · US

Funding

TRAINING IN ALCOHOL TREATMENT RESEARCHT32AA007474 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J. Woodward · 1987 to 2026
$8.5M
A Randomized Controlled Trial of Varenicline for Adolescent Smoking CessationU01DA031779 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GRAY, KEVIN M · 2012 to 2016
$3.3M
Translational Neuropsychopharmacology Research of Nicotine AddictionR01DA038700 · NIDA · UNIVERSITY OF MISSOURI-COLUMBIA · PI FROELIGER, BRETT · 2015 to 2019
$2.9M
A Controlled Trial of N-Acetylcysteine (NAC) in Cannabis Dependent AdolescentsR01DA026777 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GRAY, KEVIN M · 2009 to 2010
$722k
NIAAA NIH HHS T32 AA007474NIDA NIH HHS R01 DA026777NIDA NIH HHS R01 DA038700NIDA NIH HHS U01 DA031779
6 · The paper itself

Abstract

backgroundIn light of recent progress toward pharmacologic interventions to treat adolescent cannabis use disorder, it is important to consider which adolescent characteristics may be associated with a favorable response to treatment. This study presents secondary analyses from a parent randomized controlled trial of N-acetylcysteine (NAC) in adolescents with cannabis use disorder. We hypothesized that high pretreatment impulsivity and medication non-adherence would be associated with reduced abstinence rates.

methodsParticipants were treatment-seeking adolescents (N=115) who met criteria for cannabis use disorder and were assessed for pretreatment impulsivity. They received 1200 mg NAC or placebo orally twice daily for 8 weeks. An intent-to-treat analysis using a repeated-measures logistic regression model was used to relate pretreatment impulsivity (Barratt Impulsiveness Scale) and treatment group to abstinence rates, measured by urine cannabinoid tests. To explore mechanisms by which NAC may reduce cannabis use, relationships between impulsivity, adherence, and abstinence were assessed in a second statistical model using data from participants with recorded adherence and urine cannabinoid test results (n=54).

resultsIn the intent-to-treat analysis, low pretreatment impulsivity, NAC treatment, and negative baseline urine cannabinoid test results independently increased the odds of having negative urine cannabinoid tests during treatment (OR=2.1, 2.3, and 5.3 respectively). In the sample of participants with adherence data (n=54), adherence tripled the odds of abstinence. Notably, the effect of adherence on abstinence was only observed in the NAC treatment group. Lastly, although the highly impulsive participants had reduced rates of abstinence, highly impulsive individuals adherent to NAC treatment had increased abstinence rates compared to non-adherent individuals.

conclusionLow impulsivity, NAC treatment, medication adherence, and baseline negative cannabinoid testing were associated with increased rates of abstinence in adolescents seeking treatment for cannabis use disorder. Efforts to optimize pharmacotherapy adherence may be particularly crucial for highly impulsive individuals. Understanding and addressing factors, such as impulsivity and adherence, which may affect outcomes, may aid in the successful evaluation and development of potentially promising pharmacotherapies.

Indexed as

Impulsive BehaviorAcetylcysteineAdolescentFemaleHumansMaleMarijuana AbuseMedication AdherenceYoung AdultAcetylcysteineAbstinenceAdolescentCannabisImpulsivityMarijuanaN-acetylcysteineNon-adherencePharmacotherapyYouth

Identifiers

PMID26827257
PMCPMC4775311
OpenAlexW2208036127

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.